Federal Supply Schedule 36F79719D0033

Award Date 12/1/18
Last Date to Order 5/31/25
Ultimate Awardee
Cardinal Health, Inc.
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract to The Harvard Drug Group, L.L.C., a subsidiary of Cardinal Health, Inc. The $420,103,330.00 multiple-award contract is for the 65 I B category of Drugs, Pharmaceuticals, and Hematology Related Products, with a period of performance through May 31, 2030. As an unrestricted contract, The Harvard Drug Group will provide a wide range of pharmaceutical and medical consumable products to support the VA's...
The federal contract IDV SPE2D019D0002 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to The Harvard Drug Group, L.L.C., a subsidiary of Cardinal Health, Inc. The contract has a ceiling value of $9,173,347.42 and a period of performance running through November 30, 2028. It is a single-award Indefinite Delivery Contract with no set-asides. The contract aims to procure a wide range of essential pharmaceutical and medical products, including acetaminophen, aspirin,...
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency's (DLA) Medical Supply Chain division to Cardinal Health, Inc. to provide a comprehensive range of pharmaceutical and medical products to the TRICARE West program. The contract, valued at over $773,677.24, has a base period through February 21, 2023 and includes firm fixed-price delivery orders for radiopharmaceuticals used in medical imaging procedures within the Department of Veterans Affairs (VA) healthcare...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to Cardinal Health, Inc., a global healthcare services and products company, for the Pharmaceutical Prime Vendor Fleet program. The contract, valued at $4,999,999.00, is for the provision of a comprehensive range of pharmaceutical and medical products, including prescription medications, over-the-counter drugs, vaccines, and medical consumables, to support military treatment facilities and deployed troops...
This Federal Supply Schedule (FSS) contract ID 36F79721D0257 was awarded by the Department of Veterans Affairs (VA) to Amdipharm LIMITED, a for-profit organization. The contract is for Drugs, Pharmaceuticals, & Hematology Related Products under the FSS-61-IB Pharmaceuticals and Drugs schedule, with a ceiling value of $182,000,000 and a period of performance through September 28, 2026. The contract aims to procure a wide range of pharmaceutical and drug products for use by the VA and its 12th...
The U.S. Department of Defense (DOD) Defense Logistics Agency (DLA) awarded an Indefinite Delivery Contract (IDC) to Cardinal Health, Inc., a global healthcare services and products company, for the provision of pharmaceutical products and medical supplies. The single-award IDC, valued at $6,950,000.00, is with the VA's Veterans Integrated Service Network 21 and focuses on delivering radiopharmaceuticals used in medical imaging procedures to VA healthcare facilities. The contract is structured...
The Federal Supply Schedule contract awarded to Purdue Pharma LP by the Department of Veterans Affairs' Health Administration network provides a $243,488,600.00 multiple award indefinite delivery vehicle for pharmaceuticals and drugs under GSA Schedule 65 IB. The 5-year contract, which runs from May 2022 to April 2027, allows the VA's Veterans Integrated Service Network 12 to place task orders for a variety of prescription and over-the-counter medications commonly used in hospital and clinical...
The U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded Scpharmaceuticals Inc., a for-profit pharmaceutical company based in Lexington, MA, a Federal Supply Schedule (FSS) contract valued at $600,875.40. This multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract, designated as FSS 65 IB, covers the provision of drugs, pharmaceuticals, and hematology-related products to VA facilities over a five-year period ending in November 2028. In...
The Department of Veterans Affairs (VA) awarded an indefinite delivery contract (IDC) to Cardinal Health 414, LLC, a subsidiary of the global healthcare services company Cardinal Health, Inc. The contract, valued at $350,000, is for the manufacturing and delivery of radiopharmaceuticals to VA medical centers. This single-award IDC has a base period of performance from November 12, 2024 to November 11, 2025. Under this contract, Cardinal Health 414 will provide a range of radiopharmaceuticals,...
The Department of Veterans Affairs (VA) Veterans Health Administration has awarded a Federal Supply Schedule (FSS) contract to Vistapharm, Inc., a for-profit manufacturer of pharmaceutical goods. The contract, with a potential value of $20,359,397, is under the VA's Veterans Integrated Service Network 12 and is part of the Pharmaceuticals and Drugs (FSS-61-IB) master schedule. The contract has a period of performance from September 30, 2017, to March 31, 2024, and does not utilize any...

The Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract, contract number 36F79719D0033, to The Harvard Drug Group, L.L.C., a subsidiary of Cardinal Health, Inc. This multiple-award contract is under the Pharmaceuticals and Drugs (FSS-61-IB) schedule and has a ceiling value of $452,567,150.00, with a period of performance through May 31, 2025.

The contract is designed to provide the VA, Department of Defense, and other federal healthcare agencies with a wide range of pharmaceutical and medical products, including over-the-counter medications, prescription drugs, medical supplies, and specialty medications. The Harvard Drug Group, L.L.C. has also been awarded a separate single-award indefinite delivery contract (IDC) by the VA National Acquisition Center for the supply of Lurasidone Hydrochloride tablets, valued at $10,056,938.10. Additionally, Cardinal Health, Inc., the parent company of The Harvard Drug Group, L.L.C., holds its own significant IDC with the VA for the provision of radiopharmaceutical products to support medical imaging procedures, valued at $773,677.24.

Generated 3/30/25, 12:49 AM